NCT00777114View on ClinicalTrials.gov

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 1, 2007

Primary Completion Date

December 18, 2012

Study Completion Date

December 18, 2012

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

bortezomib, tositumomab

"1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."

Trial Locations (2)

10021

Weill Cornell Medical College, New York

Unknown

University of Michigan, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER